Search

Your search keyword '"Freedland, S"' showing total 321 results
Start Over Author "Freedland, S"
321 results on '"Freedland, S"'

3. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Author

Freedland, S. J., Almeida Luz, M. de, Giorgi, U. De, Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., Tarazi, J., Sridharan, S., Sugg, J., Tang, Y., Tutrone Jr., R. F., Venugopal, B., Villers, A., Woo, H. H., Zohren, F., and Shore, N. D.

Subjects
*CLINICAL trials, *PROSTATE cancer, *PROSTATE cancer patients, *LEUPROLIDE, *PROSTATE-specific antigen
Abstract

BACKGROUND Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus an- drogen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown. METHODS In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less. Patients were randomly assigned, in a 1:1:1 ratio, to receive enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), or enzalutamide monotherapy (monotherapy group). The primary end point was metastasis-free survival, as assessed by blinded independent central review, in the combination group as compared with the leu- prolide-alone group. A key secondary end point was metastasis-free survival in the monotherapy group as compared with the leuprolide-alone group. Other secondary end points were patient-reported outcomes and safety. RESULTS A total of 1068 patients underwent randomization: 355 were assigned to the com- bination group, 358 to the leuprolide-alone group, and 355 to the monotherapy group. The patients were followed for a median of 60.7 months. At 5 years, metastasis-free survival was 87.3% (95% confidence interval [CI], 83.0 to 90.6) in the combination group, 71.4% (95% CI, 65.7 to 76.3) in the leuprolide-alone group, and 80.0% (95% CI, 75.0 to 84.1) in the monotherapy group. With respect to metastasis-free survival, enzalutamide plus leuprolide was superior to leuprolide alone (hazard ratio for metastasis or death, 0.42; 95% CI, 0.30 to 0.61; P<0.001); enzalutamide monotherapy was also superior to leuprolide alone (hazard ratio for metastasis or death, 0.63; 95% CI, 0.46 to 0.87; P=0.005). No new safety signals were observed, with no substantial between-group differences in quality-of-life measures. CONCLUSIONS In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis- free survival; enzalutamide monotherapy was also superior to leuprolide alone. The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. 1384P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019

Author

George, D.J., primary, Sandin, R., additional, Agarwal, N., additional, Tagawa, S.T., additional, Klaassen, Z., additional, Bitting, R., additional, Ramaswamy, K., additional, Emir, B., additional, Bland, C., additional, Hong, A., additional, Shi, L., additional, Yang, H., additional, Gao, W., additional, Song, W., additional, and Freedland, S., additional

Published
2022
Full Text
View/download PDF

48. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer

Author

Yang, L, Roberts, D, Takhar, M, Erho, N, Bibby, B, Thiruthaneeswaran, N, Bhandari, V, Cheng, W, Haider, S, McCorry, A, McArt, D, Jain, S, Alshalalfa, M, Ross, A, Schaffer, E, Den, R, Jeffrey Karnes, R, Klein, E, Hoskin, P, Freedland, S, Lamb, A, Neal, D, Buffa, F, Bristow, R, Boutros, P, Davicioni, E, Choudhury, A, and West, C

Subjects
Urologic Diseases, Male, Aging, Prognostic biomarker, Clinical Sciences, lcsh:Medicine, Gene expression signature, Disease-Free Survival, SDG 3 - Good Health and Well-being, Clinical Research, Genetics, Humans, Neoplasm Metastasis, Hypoxia, Cancer, lcsh:R5-920, screening and diagnosis, Neoplastic, Prostate cancer, Manchester Cancer Research Centre, Radiotherapy, ResearchInstitutes_Networks_Beacons/mcrc, lcsh:R, Prostatic Neoplasms, 4.1 Discovery and preclinical testing of markers and technologies, Gene Expression Regulation, Neoplastic, Survival Rate, Detection, Gene Expression Regulation, Public Health and Health Services, Tumor Hypoxia, Patient Safety, lcsh:Medicine (General)
Abstract

Background: Hypoxia is associated with a poor prognosis in prostate cancer. This work aimed to derive and validate a hypoxia-related mRNA signature for localized prostate cancer. Method: Hypoxia genes were identified in vitro via RNA-sequencing and combined with in vivo gene co-expression analysis to generate a signature. The signature was independently validated in eleven prostate cancer cohorts and a bladder cancer phase III randomized trial of radiotherapy alone or with carbogen and nicotinamide (CON). Results: A 28-gene signature was derived. Patients with high signature scores had poorer biochemical recurrence free survivals in six of eight independent cohorts of prostatectomy-treated patients (Log rank test P

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results